|
KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non‒clear cell renal cell carcinoma (NCC-RCC). |
|
|
Honoraria - Amgen; Astellas Pharma; Bristol-Myers Squibb |
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Pfizer; Sanofi/Aventis |
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
|
|
Honoraria - Acraf; Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre |
|
|
No Relationships to Disclose |
|
Vsevolod Borisovich Matveev |
Consulting or Advisory Role - Bayer; Eisai |
Travel, Accommodations, Expenses - Bayer |
|
|
No Relationships to Disclose |
|
|
Research Funding - Ipsen (Inst); Novartis (Inst); Pfizer (Inst) |
|
|
Honoraria - Abbvie; Amgen; Astellas Pharma; Bayer; Genzyme; Janssen; Roche; Sanofi |
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Genzyme; Janssen; Sanofi |
|
Travel, Accommodations, Expenses - Abbvie; Astellas Pharma; Bayer; Genzyme; Janssen; Sanofi |
|
Boris Yakovlevich Alekseev |
Research Funding - Astellas Pharma; AstraZeneca; Janssen; Merck; Roche |
|
|
Honoraria - Astellas Pharma; Ipsen; Pfizer |
Consulting or Advisory Role - Astellas Pharma; Ipsen; Pfizer |
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen; Pfizer |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi |
Consulting or Advisory Role - Bayer; Bayer; Bristol-Myers Squibb; Celgene; Eisai; Janssen-Cilag; Merck; Pfizer; Roche/Genentech; Sanofi |
Travel, Accommodations, Expenses - Ipsen; Janssen; Merck; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
Consulting or Advisory Role - alkermes; Array BioPharma; Bristol-Myers Squibb; EMD Serono; exelixis; Genentech/Roche; Jounce Therapeutics; Lilly; Merck; Novartis; Peloton Therapeutics; Pfizer; X4 Pharma |
Research Funding - alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Prometheus (Inst) |
Other Relationship - Beth Israel Deaconess Medical Center; Various |
|
|
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - Acceleron Pharma; Aduro Biotech; Agenus; Array BioPharma; Arrowhead Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Glactone Pharma; Immunocore; Iovance Biotherapeutics; Merck; Newlink Genetics/Pharmatech; Novartis; Oncolys BioPharma; Pfizer; Surface Oncology; Werewolf Pharma; X4 Pharma |
Research Funding - Bristol-Myers Squibb (Inst) |